Cryo-Cell International, Inc. Quarterly report pursuant to Section 13 or 15(d)

Notes Payable (Tables)

6 Months Ended

May 31, 2024

As of May 31, 2024 and November 30, 2023, the note payable obligation was as follows:


	May 31, 2024			November 30, 2023
Note payable - Susser	$	8,686,712		$	8,765,082
Unamortized debt issuance costs - Susser		(158,735	)		(169,404	)
Net note payable	$	8,527,977		$	8,595,678
Current portion of note payable	$	171,605		$	165,641
Long-term note payable, net of debt issuance costs		8,356,372			8,430,037
Total	$	8,527,977		$	8,595,678

Interest expense on the note payable for the three and six months ended May 31, 2024 and 2023 was as follows:


	For the three months ended		For the six months ended
	May 31, 2024		May 31, 2024
Interest expense on notes payable - Susser	$	47,166	$	47,166
Debt issuance costs - Susser		—		—
Total interest expense	$	47,166	$	47,166


	For the three months ended		For the six months ended
	May 31, 2023		May 31, 2023
Interest expense on notes payable - Susser	$	204,206	$	406,681
Debt issuance costs - Susser		5,418		10,862
Total interest expense	$	209,624	$	417,543